文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

COVID-19相关急性肾损伤与远期肾脏结局

COVID-19-Associated Acute Kidney Injury and Longitudinal Kidney Outcomes.
PubMed 文献 · JAMA Intern Med · 2024-01-01
一句话结论多中心回顾性队列显示,COVID-AKI存活者出院后2年内主要不良肾脏事件(MAKE)风险低于同期其他疾病相关AKI(aHR 0.67)。

该回顾性纵向多中心队列研究纳入2020年3月至2022年6月住院、筛查SARS-CoV-2、发生AKI且存活出院的成人患者987例COVID-AKI,以及同期8361例其他疾病相关AKI(other-AKI),并设276例2016年10月至2020年1月流感相关AKI历史对照,随访至出院后最长2年。主要终点MAKE为死亡与肾功能恶化(eGFR较出院时下降≥25%或肾衰竭需透析)的复合终点。校正多因素后,COVID-AKI组MAKE低于other-AKI组(aHR 0.67;95%CI 0.59-0.75),全因死亡(aHR 0.31;95%CI 0.24-0.39)与肾功能恶化(aHR 0.78;95%CI 0.69-0.88)均更低。提示COVID-AKI存活者远期肾脏与生存结局不劣于、甚至优于其他疾病相关AKI。

要点

  • COVID-AKI组出院后最长2年MAKE低于other-AKI组:aHR 0.67(95%CI 0.59-0.75)。
  • COVID-AKI组全因死亡低于other-AKI组:aHR 0.31(95%CI 0.24-0.39)。
  • COVID-AKI组肾功能恶化(eGFR较出院下降≥25%或需透析)低于other-AKI组:aHR 0.78(95%CI 0.69-0.88)。
  • COVID-AKI患者较其他两组更年轻、基线eGFR更高、基线合并症评分更差、病情严重度指标更高、住院时间更长。
  • 研究为回顾性纵向多中心队列,随访最长2年,数据来自电子健康记录。

适用人群与场景

  • 成人住院患者,发生AKI且存活出院:2020年3月至2022年6月COVID-19大流行期间住院并筛查SARS-CoV-2者,或2016年10月至2020年1月大流行前5年内住院、甲型或乙型流感检测阳性者。
  • 随访最长为出院后2年。

诊断标准与关键阈值

  • 主要终点MAKE定义为死亡与肾功能恶化的复合终点,肾功能恶化指eGFR较出院时下降≥25%或肾衰竭需透析。

研究设计与关键结果

  • 研究类型:回顾性纵向多中心队列研究,使用大型医院系统电子健康记录数据,分析时间为2022年12月至2023年11月。
  • 样本量:9624例住院AKI患者,其中COVID-AKI 987例、流感相关AKI 276例、其他疾病相关AKI(other-AKI)8361例;平均(SD)年龄69.0(15.7)岁,女性4955例(51.5%)。
  • 与other-AKI组相比,COVID-AKI组MAKE更低:aHR 0.67(95%CI 0.59-0.75)。
  • 与other-AKI组相比,COVID-AKI组全因死亡更低:aHR 0.31(95%CI 0.24-0.39)。
  • 与other-AKI组相比,COVID-AKI组肾功能恶化率更低:aHR 0.78(95%CI 0.69-0.88)。
  • 与other-AKI组及流感相关AKI组相比,COVID-AKI组年龄稍轻、基线eGFR更高、基线合并症评分更差、病情严重度指标更高、住院时间更长。

证据类型、等级与局限

  • 证据类型:回顾性纵向多中心队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,COVID-AKI住院存活者相比其他疾病相关AKI患者,MAKE、远期肾功能下降和死亡风险更低。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: COVID-19 infection is associated with a high incidence of acute kidney injury (AKI). Although rapid kidney function decline has been reported in the first few months after COVID-19-associated AKI (COVID-AKI), the longer-term association of COVID-AKI with kidney function remains unknown.

OBJECTIVE: To assess long-term kidney outcomes of patients who had COVID-19-associated AKI.

DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective longitudinal multicenter cohort study conducted in a large hospital system using electronic health records data on adult hospitalized patients with AKI and COVID-19 or other illnesses. Included patients were hospitalized during the COVID-19 pandemic (March 2020-June 2022), were screened for SARS-CoV-2, had AKI, and survived to discharge, or had been hospitalized during the 5 years before the pandemic (October 2016-January 2020), had a positive influenza A or B test result, had AKI, and survived to discharge. Patients were followed up for a maximum of 2 years after hospital discharge. Data analyses were performed from December 2022 to November 2023.

EXPOSURE: COVID-19 and influenza.

MAIN OUTCOMES AND MEASURES: The primary outcome was major adverse kidney events (MAKE), defined as a composite of mortality and worsened kidney function (estimated glomerular filtration rate [eGFR] decline by ≥25% from discharge eGFR or kidney failure requiring dialysis). Multivariable time-to-event analyses were performed to compare MAKE between individuals with COVID-AKI and those who had AKI associated with other illnesses hospitalized during the same period. For further comparison, this outcome was assessed for a historic cohort of patients with influenza-associated AKI.

RESULTS: The study cohort included 9624 hospitalized patients (mean [SD] age, 69.0 [15.7] years; 4955 [51.5%] females) with AKI, including 987 patients with COVID-AKI, 276 with influenza-associated AKI, and 8361 with AKI associated with other illnesses (other-AKI). Compared with the other 2 groups, patients with COVID-19-associated AKI were slightly younger in age, had a higher baseline eGFR, worse baseline comorbidity scores, higher markers of illness severity, and longer hospital stay. Compared with the other-AKI group, the COVID-AKI group had lower MAKE (adjusted hazard ratio [aHR], 0.67; 95% CI, 0.59-0.75) due to lower all-cause mortality (aHR, 0.31; 95% CI, 0.24-0.39) and lower rates of worsened kidney function (aHR, 0.78; 95% CI, 0.69-0.88).

CONCLUSIONS AND RELEVANCE: The findings of this multicenter cohort study indicate that survivors of hospitalization with COVID-AKI experience lower rates of MAKE, long-term kidney function decline, and mortality compared with patients with AKI associated with other illnesses.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Aklilu AM, Kumar S, Nugent J, et al. COVID-19-Associated Acute Kidney Injury and Longitudinal Kidney Outcomes. JAMA Intern Med. 2024. PMID: 38407862. doi:10.1001/jamainternmed.2023.8225

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。